BioAtla, Inc. (BCAB)
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioAtla, Inc.
BioAtla, Inc. (BCAB) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 32 SEC filings.
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 2 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.